These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11144705)

  • 1. Cefdinir: an expanded-spectrum oral cephalosporin.
    Guay DR
    Ann Pharmacother; 2000 Dec; 34(12):1469-77. PubMed ID: 11144705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin.
    Guay DR
    Clin Ther; 2002 Apr; 24(4):473-89. PubMed ID: 12017394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftibuten: a new expanded-spectrum oral cephalosporin.
    Guay DR
    Ann Pharmacother; 1997 Sep; 31(9):1022-33. PubMed ID: 9296244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin.
    Guay DR
    Clin Ther; 2001 Dec; 23(12):1924-37; discussion 1923. PubMed ID: 11813929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of in vitro activity, pharmacokinetic characteristics, safety, and clinical efficacy of cefprozil, a new oral cephalosporin.
    Barriere SL
    Ann Pharmacother; 1993 Sep; 27(9):1082-9. PubMed ID: 8219444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002).
    Sader HS; Fritsche TR; Mutnick AH; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):515-25. PubMed ID: 14596971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections.
    Sader HS; Jones RN
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):29-43. PubMed ID: 17266451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
    París MM; Devcich KJ
    Cutis; 2004 May; 73(5 Suppl):14-8. PubMed ID: 15182160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of cefdinir in acute bacterial rhinosinusitis.
    Hadley JA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1075-83. PubMed ID: 16722817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.
    Wiseman LR; Benfield P
    Drugs; 1993 Feb; 45(2):295-317. PubMed ID: 7681376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.
    Guay DR
    Pediatr Infect Dis J; 2000 Dec; 19(12 Suppl):S141-6. PubMed ID: 11144395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily.
    Bowlware KL; McCracken GH; Lozano-Hernandez J; Ghaffar F
    Pediatr Infect Dis J; 2006 Mar; 25(3):208-10. PubMed ID: 16511381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefdinir: in vitro activity study and effect of human serum.
    García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
    Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.
    Wise R; Andrews JM; Thornber D
    J Antimicrob Chemother; 1991 Aug; 28(2):239-48. PubMed ID: 1778855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.
    Sader HS; Biedenbach DJ; Streit JM; Jones RN
    Int J Antimicrob Agents; 2005 Jan; 25(1):89-92. PubMed ID: 15620832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.